Počet záznamov: 1
adalimumab
SYS d000068879 LBL 00000cz--a2200181n--4500 005 20250606221740.4 008 160101|||anznnbabn-----------|-a|a------ 040 $b slo $a BA006 $d BA006 $d BA006 065 $a D12.776.124.486.485.114.224.060.250 065 $a D12.776.124.790.651.114.224.060.250 065 $a D12.776.377.715.548.114.224.200.250 066 $a 01 $c 03 150 $a adalimumab $x AD $x AE $x AN $x BI $x BL $x CF $x CH $x CL $x DE $x EC $x GE $x HI $x IM $x IP $x ME $x PD $x PH $x PK $x PO $x RE $x TO $x TU $x UL $x UR $2 slo 450 $w v $a protilátka D2E7 $2 slo 450 $w v $a adalimumab-adbm $2 slo 450 $w v $a adalimumab-atto $2 slo 450 $w v $a Amjevita $2 slo 450 $w v $a Cyltezo $2 slo 450 $w v $a Humira $2 slo 550 $7 sllk_us_auth*d014409 $Y Tumor Necrosis Factor-alpha $w b $a faktor nekrotizujúci nádory, alfa 550 $7 sllk_us_auth*d018501 $Y Antirheumatic Agents $w P $a antireumatiká 550 $7 sllk_us_auth*d000079424 $Y Tumor Necrosis Factor Inhibitors $w P $a inhibítory faktora nekrotizujúceho nádory 550 $7 sllk_us_auth*d014409 $Y Tumor Necrosis Factor-alpha $w p $a faktor nekrotizujúci nádory, alfa 665 $a 2016 (2002) $2 eng 680 9-
$i A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS. $2 eng 750 -2
$a Adalimumab $2 eng 980 $x M
Počet záznamov: 1